Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Explore Activities by Sara M. Tolaney

Title
Format
Credit Type
Credits
Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC

Content Format:

Text Module

Credit Type:

AAPA | ABIM MOC | ACPE | AMA | ANCC

Credits:

0.50
Integration of Novel Antibody–Drug Conjugates in Advanced HER2-Low, Hormone Receptor–Positive, and Triple-Negative Breast Cancer

Content Format:

PDF

Credit Type:

--

Credits:

--
InterACT Oncology Team Training: Improving Clinical Outcomes for Patients With High-Risk HR-Positive/HER2-Negative Early-Stage Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

Content Format:

Podcast Episodes

Credit Type:

AMA

Credits:

0.75
Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations

Content Format:

Slideset

Credit Type:

--

Credits:

--
Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER2 Expression in Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
How I Manage Key Toxicities With Adjuvant CDK4/6 Inhibitors for Early Breast Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Conference to Clinic: Breast Cancer

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
An Expert’s Guide to ASCO 2023: Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
ExpressPointsCDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Update: Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC: Downloadable Slides

Content Format:

Slideset Download

Credit Type:

--

Credits:

--